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Abstract
This article addresses an area that has been largely underserved by the development community, and one in
which there is a particularly good opportunity for the private sector to take a lead in making a difference to
employees, customers and local communities: chronic, non-communicable diseases (NCDs). It highlights the extent
of the epidemic of NCDs in developing countries, sets out the ‘business case’ for the private sector to act on NCDs,
and gives examples of initiatives by business to ensure that the healthy choice really is an easier choice for
employees, consumers and local communities. It makes the case that, to be genuinely sustainable, businesses
should be addressing health as a core part of what they do and, by working in partnership - as called for by the
Millennium Development Goals - they can make a real difference and become part of the solution. Identifying
ways in which this can be done should form a key part both of planning for, and action after, the UN High-level
Meeting on NCDs, to be held in September 2011.
1. Introduction: Business - a force for good?
Industry can be a force for real good in developing
countries, with the private sector providing jobs and
income for employees and their families, goods and ser-
vices for consumers, and tax revenue and capacity-build-
ing opportunities for governments. The impact of
business may even be greater than that of governments
with their often-limited resources - in an estimate of the
100 largest economies in the world in 2009, 44 were
businesses rather than national economies [1]. ‘Big busi-
ness’ is often regarded with mistrust, with companies
being criticised for focusing solely on profits and failing
to take account of the impact of their activities.
Whether this takes the form of environmental pollution,
the sale of dangerous products, inappropriate marketing
or the ill-treatment of workers, this can sometimes
imperil its ‘licence to operate’. However, the importance
of working with responsible businesses to achieve pov-
erty reduction has been acknowledged by the Millen-
nium Development Goals (MDGs), established in 2000,
Goal 8 of which calls for a ‘global partnership for devel-
opment’, incorporating the private sector, notably (but
not exclusively) the pharmaceutical industry and new
technologies [2]. Industry can take a role, particularly
where the government is not - or cannot - protect the
health of its people.
This article focuses on an area that has been largely
underserved by the development community, and one in
which there is a particularly good opportunity for busi-
nesses to take a lead in making a difference to employ-
ees, customers and local communities: chronic, non-
communicable diseases (NCDs). The four major NCDs -
cardiovascular disease, cancers, type 2 diabetes and
chronic respiratory disease - are responsible for the
majority of the global disease burden. This epidemic has
been rapidly escalating in developing countries - and, in
recognition of this, the United Nations is to hold a
major, High-level Meeting (referred to here as the ‘UN
Summit’) in September 2011, to discuss the issue [3].
There is no time to lose, as NCDs threaten to over-
whelm health systems in developed and developing
countries alike.
There is a significant precedent for businesses taking a
lead in a multi-factor, multi-stakeholder issue: action on
the environment. Over the last few years, environmental
issues have gone from a niche topic debated by experts
and activists, to mainstream debate, and have moved
from philanthropy to become part of ‘corporate social
responsibility’. Decisions on environmental impacts are
often now deeply embedded in business models and
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strategies, with green technologies and processes becom-
ing an important driver of economic growth and oppor-
tunity. Health - including NCDs - should be the next
wave.
This article sets out the case for action and for the
potentially key role that the private sector can and
should play in preventing and managing NCDs in devel-
oping countries, within its own sphere of influence and
by assisting governments in discharging their
responsibilities.
In writing this article, the authors have all drawn on
their extensive practical experience in this field, as well
as knowledge gained through discussion and presenta-
tions on prevention and control on NCDs at confer-
ences and meetings with diverse stakeholders.
2. The scale of the epidemic of NCDs
The shift in the burden of disease in developing coun-
tries from infectious diseases to NCDs has been driven
by a number of factors, often indicative of economic
development: a move from traditional foods to pro-
cessed foods high in fat, salt and sugar, a decrease in
physical activity as jobs - and lifestyles - become more
sedentary, and changed cultural norms (such as increas-
ing numbers of women using tobacco). In addition,
there is better access to vaccinations and drugs to pre-
vent and treat infectious diseases, often through aid pro-
grammes such as the Global Alliance for Vaccines and
Immunisation (GAVI) and the Global Fund to Fight
AIDS, Tuberculosis and Malaria. But NCDs have been
rising - and will continue to do so: the World Health
Organization (WHO) estimates that in Africa, deaths
from NCDs will rise by 27 per cent between 2005 and
2015, and that in SE Asia infectious disease deaths will
fall by 16 per cent while NCD deaths will rise by 21 per
cent [4].
The tragedy is that much of this burden is preventa-
ble, through tackling poor diet, tobacco use and lack of
physical activity. Diabetes currently affects at least 285
million people around the world, expected to rise to 438
million within 20 years, [5] but at least 50 per cent of
type 2 diabetes cases could be prevented or delayed in
people with pre-diabetes or with known risks for devel-
oping the disease by adopting a healthy diet and increas-
ing physical activity [6]. In addition, many of the 17+
million deaths each year from cardiovascular disease -
the world’s biggest killer, with 82 per cent of the deaths
occurring in low- and middle-income countries [7] -
could also be prevented.
Demographic changes have a significant impact on
non-communicable diseases - it is a sign of great pro-
gress that fewer people die young from infectious dis-
eases - but healthy ageing is increasingly threatened by
the rise in NCDs. For example, recent evidence from
Canada has shown that the presence of chronic condi-
tions, such as diabetes, has a much greater impact on
health-care resources than age alone [8]. A further study
in Matlab, Bangladesh, showed what the authors
describe as a ‘massive change’ over a 20-year period
(1986 to 2006) in the proportion of deaths from non-
communicable diseases compared to infectious diseases
- however, there was not a large ageing effect during
this time period, so the change was not simply due to
increased longevity [9].
In any case, NCDs do not affect only the elderly: many
who develop NCDs in developing countries do so at a
relatively young age - a recent study of 23 low- and
middle-income countries found that 43% of NCD deaths
were among those aged under 70 [10]. Where there is
very limited access to essential medicines and other
treatments, this is likely to impair younger people’s abil-
ity to work, or remove them (and their carers) from the
workforce. It is a terrible irony that, once the poorest
are removed from the deepest poverty, lifestyle changes
may lead to long-term health problems. In addition, a
dual burden of infectious and non-communicable dis-
eases is often faced (and with links between them - for
example, diabetes increases the risk of contracting
tuberculosis [11]), with different diseases affecting differ-
ent family members.
That this is a development issue should be self-evi-
dent: NCDs affect the incomes of individuals, families
and governments. This is ageing without wealth and, as
Judith Mackay of the World Lung Federation has put it:
‘It is hard to see how the [MDGs] can be achieved with-
out addressing NCDs, especially for the goals related to
health outcomes, poverty and hunger.’ [12] Economic
development is clearly threatened by NCDs - for exam-
ple, the WHO estimated that the national income fore-
gone in India between 2005 and 2015 due to stroke,
heart disease and diabetes would be $236 billion, around
1 per cent of GDP [13].
As one example, spending on one of the major risk
factors for NCDs, tobacco (the use of which killed 6
million people in 2010, 72% of whom lived in low- and
middle-income countries [14]), can ‘crowd out’ spending
on other essentials such as education and food among
the poorest. A 2001 study in Bangladesh, for example,
found that the money typically spent by a poor family
on tobacco could add 500 calories a day to the diets of
one or two undernourished children [15].
And yet, NCDs have not been a priority, either for
development agencies or for companies doing business
in developing countries. The extent - and speed of tran-
sition - of the epidemic of NCDs has not been fully
appreciated, and NCDs are often, wrongly, perceived to
be ‘diseases of affluence’, when in fact they often hit the
poorest hardest. Infectious diseases such as HIV/AIDS,
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tuberculosis and malaria, included in the MDGs, have
often been prioritised, and great progress has been
made. However, working to achieve a more holistic
approach to health, working across the health system as
a whole, can help to tackle both infectious and non-
communicable diseases more effectively than working
within disease ‘silos’ [16].
3. Why should business act on NCDs?
Industry has often ignored the negative effect of busi-
ness activity on national or workplace health, as busi-
nesses have not been held economically, politically or
morally responsible for the consequences of their
actions. This responsibility goes beyond the impacts of
environmental pollution and other high-profile health
issues: there are also the more insidious impacts of
tobacco, sedentary lifestyles, overconsumption of foods
high in fat, sugar and salt, and unhealthy workplaces
and working practices.
There are many arguments for private-sector action
on NCDs. First, there is the profit motive - namely that
the drain that NCDs will put on the economy in the
coming decades will threaten future profits. This risk is
serious: the World Economic Forum’s ‘Global Risks’
project has identified NCDs as being one of the greatest
threats to the global economy in 2010, with only risks
such as asset price collapse being seen as both more
likely and with the potential for greater economic
loss [17]. For example, a major epidemic in the develop-
ing world would lower worker productivity in BRIC
countries (Brazil, Russia, India and China) with reper-
cussions going far beyond the companies operating
within those countries, affecting pensions and other
investments in the wider economy.
A second reason why the private sector is well placed
to tackle NCDs is because businesses often plan for per-
iods much longer than that of the political cycle - and
this long timescale is particularly appropriate to addres-
sing the risk factors for NCDs (in contrast to addressing
infectious diseases, which require rapid responses, often
more conducive to immediate development solutions).
Given that the potential rise in ill-health and fall in pro-
ductivity due to NCDs over the next 20 years is threa-
tening the viability of business-as-usual, industry can
develop more sustainable business models that will seek
to reduce the major risk factors and promote healthy
ageing in the workforce and among consumers, benefit-
ing both the bottom line and the health of the
population.
Alone, neither industry nor government - particularly
when budgets are stretched - can reverse the growing
epidemic: we need to work together. The financial
resources, human capacity and market penetration of
business can be invaluable in creating partnerships with
the public and NGO sectors, helping to create an envir-
onment that is health-promoting, in which individuals
have the resources and knowledge needed to make
healthy choices. This need for partnership was high-
lighted in the Millennium Development Goals, and spe-
cifically by the World Health Organization’s 2008-2013
Action Plan for the Global Strategy for the Prevention
and Control of Noncommunicable Diseases, [18] which
includes as one of its six major objectives the need to
‘promote partnerships’ in NCDs. Frameworks such as
the World Business Council for Sustainable Develop-
ment are now building on the recognition that colla-
boration between private and public sectors is needed to
address the challenges of poverty, above and beyond the
MDGs - and that this includes NCDs [19] - and organi-
sations such as the Pan American Health Organization
are also engaging with business (in this case, through its
Partners Forum [20]).
By working in partnership, businesses can make a real
difference and become part of the solution. Identifying
ways in which this can be done should be a key part of
planning for the UN Summit in September 2011.
3.1 Making the business case
Taking action on NCDs is not merely a ‘nice to have’ -
it is fast becoming an attractive business proposition, an
essential part of future-proofing the business that can
improve its performance in the short, medium and long
term. True sustainability requires the prospect of long-
term return, and companies that do not take into
account the health of their workforce - and the eco-
nomic health of local and national communities - will
find that the burden of NCDs will damage this return:
every company has an interest in engaging in NCD
prevention.
The many rationales for considering NCDs in invest-
ment decisions can be divided into three clear cate-
gories: employees (keeping the workforce healthy), profit
motive (new products and new markets) and ‘beyond
business’ (doing the right thing).
3.1.1 Employees
It is in its role as employer that the vested interest of
the private sector in tackling NCDs is most obvious.
There is increasing evidence, specifically in high-income
economies, of the return on investment that can be seen
in keeping the workforce well - that an unhealthy work-
force makes for an unhealthy business. Particularly
where employers are responsible for health-care costs,
preventing NCDs through workplace health programmes
can have attractive cost-benefit ratios. A healthy work-
force is not only more likely to take less time off work
through illness (absenteeism): employees are also less
prone to ‘presenteeism’ (under-performing at work),
which can be a threat to the competitiveness of the
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company. Action can be taken on encouraging healthy
lifestyles, and also - where necessary - employers can
help with provision of early diagnosis and essential
medicines.
A meta-evaluation of 56 worksite health promotion
economic-return studies in 2005 concluded that work-
place health programmes can result in significant reduc-
tions in medical and absenteeism costs - of around 25
to 30 per cent - over a 3.6-year timescale, and had an
average 5.81:1 ratio of savings to cost [21]. The World
Economic Forum is now working, with Professor David
Bloom at Harvard University, to analyse more up-to-
date data for presentation ahead of the UN Summit in
September 2011. Working closely with employees to
design programmes - with individual employees taking
the role of champions or health advocates within the
workplace, and partnering with organised labour - often
has the most benefit.
Acting on NCDs is ‘the right thing to do’ - and, while
taking action on, for example, health and healthy life-
styles (even above and beyond what is required to raise
productivity) may not seem like the most business-
orientated decision, it is likely, in fact, to raise morale
and motivation among employees, improve the reputa-
tion of the business and increase trust in the company
among employees, consumers and government. Where a
business acts positively to foster good health, recognis-
ing and sharing this will improve trust in the company
and provide the business with further incentive to con-
tinue to make progress. A survey of over 28,000 people
in 15 countries, undertaken in 2009, found a strong cor-
relation between companies that have wellness pro-
grammes and companies that a) encourage employees to
be creative and innovative and b) that are more likely to
retain staff. (While this is not necessarily indicative of a
causal relationship, as the report notes, it gives an
insight into the levers that companies can use to
improve performance, morale and retention.) Respon-
dents who see wellness as a priority for their employer
were 3.5 times more likely to report being encouraged
to be creative than those for whom it is not a priority -
and 64% of them plan to stay for at least five years,
compared to only 42% in companies where wellness is
not prioritised [22].
3.1.2 Profit motive
All companies have to report to their shareholders, and
identify sustainable opportunities to develop new pro-
ducts or reach new markets. The profit motive may be
viewed with distrust by those not in the private sector,
as profit is not always pursued responsibly - but compe-
titive advantage can be achieved through innovative and
responsible approaches, which adapt to local realities.
These can lead to greater market share and open up
new markets as economic development increases. The
challenges of NCDs require new insights into preventing
their onset and supporting those who live with the
diseases.
The need to adapt to local realities may give compa-
nies the opportunity to identify the potential for new,
replicable and scalable innovations that will be appropri-
ate not only in the developing country itself, but more
widely. Nigel Crisp, in his book Turning the World
Upside Down, [23] cites the example of Aravind Eye
Care (in southern India), which developed new, afford-
able methodologies and materials to create an intra-ocu-
lar lens, costing just US$2 (compared to prices of up to
$200 from other manufacturers at the time). The pro-
duct now has an 8% market share and is used in 120
countries around the world [24].
The development of the polycap (or polypill) - a single
daily pill containing a number of generic drugs to pre-
vent NCDs - has also been driven by research and inno-
vation in India, where a number of companies are now
manufacturing polypills. The polypills include a statin
and several blood-pressure lowering drugs, and the pill
for secondary prevention (for people with established
disease) also contains aspirin. The potential impact of
such a pill could be startling - a report in the British
Medical Journal in 2003 [25] stated that, were the pill
to be taken by everyone over the age of 55, it could
reduce ischemic heart disease events by 88% and stroke
by 80%. The polypill can be manufactured for as little as
$1 a dose and is already available in India - but not in
most developed countries, where it and other similar
products have yet to be approved. Large-scale studies on
its benefits in practice are ongoing.
The NCD epidemic is growing: tackling it, and rever-
sing it (with knock-on effects for communities and
national economies) should be part of the sustainable
business plan of food, pharma and other industries.
There is a considerable, untapped potential market for
‘health’, in which all industries - food, media, sports,
information technology, insurance - can leverage the
fact that health considerations are becoming a major
criteria of choice in purchasing decisions.
Current delivery models for healthcare, mostly
designed for acute care, are also not adapted to deal
with the management of chronic disease, creating the
opportunity for healthcare industries to come up with
innovative approaches to, for example, early diagnosis,
compliance in treatment and remote monitoring.
3.1.3 A ‘win-win’?
A recent approach, spearheaded by Michael Porter,
highlights the opportunities for business in creating
‘shared value’ - namely, ‘policies and operating practices
that enhance the competitiveness of a company which
simultaneously advance the economic and social condi-
tions in the communities in which it operates’ [26].
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Rather than seeing business and society as ‘pitted
against each other’, this approach suggests that there are
circumstances in which there can be win-wins for busi-
ness and for society, partnering to address societal
needs and challenges that would otherwise undermine
business (such as, for example, the costs of ill health
among employees and their families).
As an example of a business and societal win-win,
Novo Nordisk in China has pursued a strategy focusing
not only on treatment but also supporting physician
training and patient education, strengthening the health-
care system, creating public awareness, and establishing
local production and R&D. This strategy has exceeded
business forecasts - by 2010 Novo Nordisk had a 62%
share of the insulin market with sales growth of 30%. As
well as being economically sustainable for the company
itself, this engagement approach has created significant
economic and social value for the Chinese society with
14,600 new jobs in the local economy and 140,000 saved
life years [27]. Education of healthcare professionals and
patients can also save billions on healthcare budgets.
Careful management of diabetes has been shown to lead
to considerable savings for Chinese society. While insu-
lin sales per patient will rise (adding US$644 to the cost
of insulin over a lifetime), the net saving to society in
terms of complications avoided is such that this cost is
more than recouped, with a further saving of US$1,820
per patient over a lifetime [28].
3.2 Where can business have an influence?
In the past, there has often been reticence within the
development community about working with business,
despite the calls for partnership in MDG 8. Why would
local NGOs, government or other organisations want to
take what can be perceived as a risk in working with a
business, and why would a business want to take the
risk of working with these partners?
The answer is that all businesses have an impact on
development and on health - through providing safe
jobs and secure income for employees, through the
taxes that increase government revenues and allow for
greater spending on public goods such as health services
- and that joint working by different stakeholders can
allow for significantly improved outcomes.
All companies are employers, providers of goods/ser-
vices, and are participants in local and national commu-
nities. These four spheres of influence can help to
prioritise what is most important for companies to con-
sider when looking to act in a way that is socially
responsible [29].
• Employees are closest to home for companies, and
are at the heart of what they do: tackling workplace
health should be a first priority. This is about moving
beyond ‘health and safety’ and occupational health
(which is often simply ‘safety’ - for which companies are
held legally responsible). Employees who are knowledge-
able and empowered are not only more productive: they
can also be powerful advocates for change within their
families and local communities.
• Consumers or customers: Some industries - notably
the tobacco, food and fitness industries - clearly play a
part in the lifestyle choices that can drive or prevent the
later development of NCDs. The pharmaceutical indus-
try also has a strong role, as highlighted in the Millen-
nium Development Goals, providing drugs to prevent,
control and treat NCDs and their risk factors. Other
industries, too - including the media and information
technology - are increasingly influential: for example,
negative influences such as encouraging overly sedentary
lifestyles, or positive influences, such as the development
of new tools such as mobile technologies to provide
easily accessible, tailored help and information, and
remote monitoring.
• Local communities: Businesses are often a focal
point within the local community, with influence over
the wellbeing not only of their employees, but also of
their families and other businesses and organisations in
the vicinity. These influences can be negative - such as
environmental pollution - or positive - such as encoura-
ging use of its health facilities by local community
groups.
• Wider influence: Finally, large companies, in parti-
cular, may have influence at national level, whether
through partnering with government, industry-wide alli-
ances or through participating in multi-sectoral action -
all of which can support systemic change and foster an
environment in which it is easier to be healthy.
Beyond the requirements set by legislation, companies
should consider taking the lead ‘closest to home’ first -
ensuring sustainability within the workforce through, for
example, setting tobacco-free policies, and carefully con-
sidering their responsibility for enabling better health
among consumers and local communities, as well as the
responsibility not to undermine legislation at national
level.
4. What can business do to ensure access to
health?
Health is defined by the World Health Organization as
‘a state of complete physical, mental and social well-
being and not merely the absence of disease or infir-
mity’. ‘Access to health’, too, goes beyond simple access
to health care - it is about empowering people to make
choices that enhance physical and mental wellbeing and
to act upon those decisions. And industry’s role is about
much more than just philanthropy or funding - it is
about working in partnership to ensure the best health
outcomes.
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4.1 Staying healthy
Access to health begins with retaining good health and
preventing disease. This requires that individuals both
know what is healthy and have the means to choose the
healthy option - both areas in which businesses can
have influence.
4.1.1 Awareness-raising and education
Raising awareness of the issues around preventing and
managing NCDs in the workplace is a step that compa-
nies can take in the short term, for example through
providing health information (perhaps through represen-
tatives of worker organisations or through trusted health
and safety representatives) and by tackling the stigma
surrounding NCDs such as diabetes and cancer.
Once people are aware of the issues surrounding
NCDs - for example, how to live healthily or identify
the symptoms of NCDs - education and training, within
and beyond the workplace, can help people to under-
stand what it is that they need to do to tackle the
diseases.
Progressive companies can share their education pro-
grammes with suppliers and other local companies, per-
haps including requiring their suppliers to abide by the
same values and programmes on workplace health.
There is precedent for health capacity-building in pro-
grammes to tackle HIV/AIDS: for example, Eskom,
South Africa’s main producer of electricity, has been
providing advice on wellness programmes, education
and voluntary counselling and testing (for HIV/AIDS) to
its suppliers, ranging from small- and medium-sized
enterprises to large companies, for several years, [30]
most recently in a three-year partnership with the South
African Business Coalition on HIV and AIDS [31].
A further step that companies can take locally is to
supply resources to help to educate health professionals
in the community, particularly on NCDs. The Commis-
sion on the Education of Health Professionals for the
21st Century has recently found, as reported in The Lan-
cet, that health professionals’ education does not prop-
erly serve populations’ needs, often with chronic
shortages of doctors, nurses and primary health work-
ers [32] - and an initiative by C3 Collaborating for
Health has found a keen interest among nurses in South
Africa for more information and assistance with addres-
sing NCDs in local communities [33].
4.1.2 Facilitating healthy lifestyle choices
Awareness and knowledge of how to act to prevent and
treat NCDs is not sufficient without a third step: facili-
tating the necessary lifestyle changes.
This is a particularly fruitful area - all companies can
take steps to facilitate lifestyle change within the work-
place, and many providers of goods and services can
also focus on creating products that encourage consu-
mers to make healthier choices in the community at
large, moving well beyond companies’ initial sphere of
influence in the workplace.
a) Making it easier to make the healthy choice at
work The chance that businesses have to promote phy-
sical activity at work is highlighted in the WHO’s Action
Plan, which highlights ‘active commuting’ and safe,
active travel to work. While transport policies and
urban planning are the responsibility of government and
local authorities, businesses can make it easier for
employees by providing facilities such as showers, or
allowing breaks of sufficient length to take a walk or
other activity. Physical inactivity is the fourth-leading
cause of death worldwide [34] and, for example, inactive
people can have twice the risk of coronary heart disease
compared to the active [35]. As well as preventing dis-
eases such as diabetes and CVD, it can also help to alle-
viate stress and musculoskeletal conditions, both of
which are the cause of significant absenteeism [36].
Providing healthy food options in work canteens is
also a way to foster good health among employees.
Nike, for example, has helped its supplier company,
Tae Kwang Vina (a Korean company, with a major fac-
tory in Viet Nam, from which this example is taken),
to implement a wide range of initiatives in adopting
Nike’s code of conduct. This included not only elimi-
nating toxic solvent-based cleaners and glue, but also
the provision of a lunch or dinner, based on a nutri-
tion programme (with which the company received
technical support). The meal is cooked on-site and
consists of rice, soup, meat and vegetables. The com-
pany could have implemented the programme half-
heartedly - but in fact embraced it, including offering
the meals for free, and with real consideration given to
dietary balance, including micro- and macronutrients.
According to the International Labour Organization,
productivity has improved (as a result both of better
nutrition and better management), with higher morale
and lower absenteeism [37].
Finally, from a western standpoint, in countries where
smoking has been banned from public places and where
smoking rates have been largely falling (with some nota-
ble exceptions in pockets of the population), it is easy to
forget that tobacco use is still a huge health hazard, and
that the habit is on the increase in many developing
countries. There is an opportunity for companies both
to educate about the impact of smoking, and to make it
easier for employees to choose the healthy option, by
adopting smoke-free policies (in countries in which
smoking in workplaces is not already banned), and by
helping access to smoking-cessation programmes. At the
very least, the private sector should support national
campaigns, such as on smoke-free legislation - but it is
also an opportunity for companies to take the lead in
health promotion.
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b) Developing new technologies New technologies -
particularly the internet and mobile phones - provide a
rich source of ways both to disseminate health informa-
tion and to collect data quickly and easily, from all parts
of the world with mobile coverage. They allow for
‘crowd-sourcing’ - engaging large groups of people to
take part in a particular task, such as providing data on
disease outbreaks (which can then be verified by more
traditional means) - as well as tracking individual data
and behaviour [38].
New technologies can also greatly assist health-care
workers on the ground. In South Africa, Vodacom (a
subsidiary of Vodafone) and medical IT company
GeoMed have been piloting a mobile-phone project,
Nompilo, since 2009. Nompilo means ‘mother of health’
in Zulu, and is also the name given to local community
care-givers, who visit patients in their own homes.
Nompilo allows these care-givers to use mobile phones
to send patients’ data to the doctors to review at the
clinics - this greatly cuts the time spent on filling in
daily activity forms (thereby allowing more patient-con-
tact time) as well as educating the care-givers them-
selves. Other partners in the pilot include three local
NGOs [39].
c) Facilitating healthy food choices Population-wide
access to affordable, healthy food products is essential in
ensuring a good diet - and the food industry has an
unparalleled capacity for marketing and promotion that
could help to facilitate healthy behaviour change. In
recognition of this, [40] and in response to the WHO’s
2004 Global Strategy on Diet, Physical Activity and
Health, [41] many of the world’s largest food companies
- General Mills, Kellogg’s, Kraft, Mars, Nestlé, PepsiCo,
Coca-Cola and Unilever - made five commitments to
the WHO’s director general, Margaret Chan, in May
2008 [42]. These written commitments cover product
composition and availability (including reformulation
and fortified foods, new healthy products and portion
control), nutrition information (on-pack where possible),
appropriate marketing and advertising to children, pro-
motion of physical activity and healthy lifestyles, and
partnership (including promoting this approach in ‘all
markets’ and encouraging other companies - including
SMEs - to do the same). Where large companies lead,
smaller companies can be encouraged to follow suit,
potentially moving well beyond what is required by
national regulation. Collaboration with the private sector
in changing diets for the better has also been explicitly
called for in recommendation 8 of the Institute of Medi-
cine’s report on Promoting Cardiovascular Health in the
Developing World [43].
PepsiCo, for example, has begun to deliver on this
commitment, [44] launching, in March 2010, a series of
commitments on global nutrition criteria across three
sectors - products (’provide more food and beverage
choices made with wholesome ingredients that contri-
bute to healthier eating and drinking’), marketplace
(’encourage people to make informed choices and live
healthier’) and communities (’actively work with global
and local partners to help address global nutrition chal-
lenges’) [45]. It has set targets including reducing salt,
saturated fat and added sugar in key brands, and by
2012 it will ‘eliminate the direct sale of full-sugar soft
drinks in primary and secondary schools around the
globe’ and ‘display calorie count and key nutrients on
our food and beverage packaging’. PepsiCo in the UK,
for example, has set a number of health targets in the
UK. The scope, boundaries, basis of reporting and inde-
pendent external assurance is set out in its Health
Report 2010 [46] and the same rigour will be applied to
annual updates on progress against these targets.
d) Incentives for participation Incentives can be an
innovative way to nudge people into making healthier
choices. South African health insurer Discovery is incen-
tivising members of its insurance scheme to take control
of their health through its ‘Vitality’ programme. Vitality
members have access to price incentives to make
healthy choices, such as discounts on healthy products
at Pick ‘n’ Pay supermarkets (with greater reductions for
those who have taken an online health check), and
smoking-cessation courses. There are also rewards when
members choose the healthy activities, such as reduced
costs of flights. Participation in the Vitality programme
is voluntary for those with Discovery insurance. Assess-
ment of data of members of the scheme (normalised for
NCD status, age, etc.) found that those who are ‘highly
engaged’ in the programme have lower admission rates
to hospital in, for example, cardiovascular disease (7.4%
lower) and endocrine and metabolic diseases (20.7%
lower), as well as shorter stays in hospital and lower
costs per patient [47].
Discovery Health has also used another form of incen-
tive - entry into a lottery - in a targeted health-promo-
tion campaign, the ‘Right to Know’ HIV testing
campaign. This was run in 2008-9 by Discovery and the
Sunday Times (South Africa), and was embraced by
many companies - including Shell, Merck and Anglo
American - as a way of encouraging their employees to
take an HIV test. Discovery Health partnered with two
pharmacy chains and negotiated preferential rates for
testing, and also encouraged people to go to their GPs
for testing, and results were given in person, along with
pre- and post-test counselling. Each month, anyone who
had the test has a chance of winning a prize of
R100,000 (US$14,500). This model could also be used to
encourage screening for NCDs and ‘know your numbers’
on the risk factors (such as cholesterol, BMI and blood
pressure).
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4.2 Beyond health promotion
Companies can do more than promoting the health of
employees and consumers: they can also take a role in
strengthening health systems for proper prevention and
control of NCDs. Monitoring the diseases and risk fac-
tors is also required, and partnering with research insti-
tutions and others to find new solutions is urgent and
necessary.
4.2.1 Managing existing conditions
Many companies already recognise their role in addres-
sing the health crisis in developing countries - most
clearly in regions with high prevalence of HIV/AIDS,
tuberculosis and malaria. This model could potentially
be extended to NCDs. Pharmaceutical companies can
improve access to medicine (for example statins, insulin
and blood-pressure-lowering drugs) in poor countries,
through donations, improving availability, ensuring qual-
ity and reducing the costs of their products - and can
also work to address NCDs in other ways, going beyond
the supply of medicines actually to support their deliv-
ery to the populations that need them.
For example, since 2001 Novo Nordisk has been offer-
ing insulin at a differential price - a maximum of 20 per
cent of the price in Europe, USA, Canada and Japan - to
the least-developed countries (as defined by the United
Nations). This differential pricing has had a major
impact both on increasing access to treatment and to
Novo Nordisk sales: in 2010, almost 350,000 people -
more than 7% of the people diagnosed with diabetes
and an increase of 30% since 2009 - were using Novo
Nordisk products in 33 of the least-developed countries;
in India, an emerging economy, it is 13%. In Yemen,
34,000 people were being treated with Novo Nordisk
insulin in 2010 compared to 3,500 in 2008. In the period
during which Novo Nordisk has introduced its differen-
tial pricing, insulin has been made more affordable,
which has improved access to diabetes care. In Mali, for
example, insulin cost 35% of GDP per capita in 2004,
but in 2009 it accounted for less than 3% of GDP per
capita - and this even assumes a 24% mark-up, as was
the case in 2004 [48]. The differential pricing policy
ensures that insulin is more available to people even in
countries with poor healthcare capacity; however, addi-
tional work is being done to improve distribution in col-
laboration with local businesses, diabetes organisations
and ministries of health, including infrastructure devel-
opment (such as establishing diabetes clinics in public
hospitals), provision of diagnostic equipment for diagno-
sis, monitoring and care, capacity-building, patient and
family education as well as advocacy to include diabetes
in national plans and priorities, and large-scale aware-
ness-raising initiatives. Private-sector initiatives like
these must be followed up with political commitment to
break down barriers to access, strengthen public
infrastructures and improve the logistics of insulin
distribution.
A further way in which companies could help to man-
age existing conditions is by utilising the extraordinary
reach of their distribution channels, often stretching
deep into rural populations - soft drinks, for example,
are, in many areas, more widely available than many
drugs. The UK-based organisation ColaLife is developing
an ‘AidPod’ - a container that fits onto a crate of bottled
drinks, which can be filled with essential medicines -
and is also creating a sustainable business model that
would incentivise the distributors through small pay-
ments at each stage. ColaLife is in discussion with local
partners in Zambia - including both Coca-Cola and the
bottlers SAB Miller - to develop a pilot. The AidPods
will initially carry diarrhoea treatment kits - but could
in future be developed to contain, for example, the
‘polypill’ to tackle NCDs [49].
4.2.2 Monitoring
In order to make the most of initiatives to raise aware-
ness, educate, facilitate lifestyle change and manage
chronic conditions, companies keen to see the difference
that they are making (which will help to make the ‘busi-
ness case’), and to be able to make continuous progress,
are well advised to monitor the impact of their pro-
grammes - beginning with an understanding of the
starting position (gathering baseline data). Monitoring of
the workforce, for example, allows the company to
assess the benefits of any investment that it is making,
and, where personal data is given privately to employees,
helps individuals to understand their own health status.
It is essential that all health data is gathered and
assessed anonymously to protect the privacy of
individuals.
Knowledge of the health status of local and national
populations can also be useful. This is likely to be
reflected in the health of the workforce, and can also
allow companies to identify possible future problem
areas and take pre-emptive action.
4.2.3 Researching
Research into ‘what works’ in NCD prevention and
management can be supported by industry in partner-
ship with local research institutions. Businesses have
great capacity for, and expertise in, market research, and
can also provide funding and share their skills to help to
build a knowledge base in developing countries. Private-
sector involvement in research has been specifically
called for in, for example, the Grand Challenges in
Chronic Non-communicable Diseases, published in Nat-
ure in 2007 [50].
UnitedHealth (a major US-based insurance health and
wellbeing company) collaborates with the US National
Heart, Lung and Blood Institute in supporting a global
network of Collaborating Centers of Excellence. Each
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Center pairs a research institution in a developing coun-
try with at least one partner academic institution in a
developed country. These Centers of Excellence are
developing infrastructures for research and training,
enhancing the capacity to conduct population-based or
clinical research to monitor, prevent, or control NCDs.
For example, the Center in Guatemala City, based at the
Institute of Nutrition of Central America and Panama
(INCAP), partners with Johns Hopkins University as
well as a number of local universities and NGOs, and
aims to ‘reduce the burden of CVD in Mesoamerica by
... carry[ing] out research, training, and capacity-building
for prevention and management of CVD and related
risk factors’ [51,52].
A further example is the private-sector support of a
six-month attachment of communications expertise
from GSK that provided a boost to efforts by the Pan
American Health Organization to address the burden of
NCDs in Latin America and the Caribbean. This
strengthened capacity for communications and advocacy
related to the prevention and control of NCDs, and
added value by bringing a more ‘marketing’-orientated
view to communications materials.
There is much that remains to be done to tackle the
epidemic - and much that we do not yet know about
the extent and impact of NCDs and the risk factors.
Data-gathering and research into what works are essen-
tial for identifying the best use of resources and the
most fruitful interventions - but there are already clear
indications of where the most fruitful interventions lie
and, particularly ahead of the UN Summit, action must
be taken now to prevent the burden of NCDs from
increasing further over the coming decades.
5. Conclusions
The private sector in developing countries - both local
companies and international businesses with multina-
tional reach - has great potential for taking a lead in
prevention, control and management of NCDs, whether
within its immediate sphere of influence (beginning with
the health of employees) or in partnership with other
organisations and actors in the wider community.
Businesses have many advantages when seeking to
address NCDs: they have the geographical presence, the
convening power and credibility within local communities,
the commitment to be involved over the long term and -
crucially - the resources to take action. Other stakeholders
- whether government, NGOs, academics or international
organisations - can look for and seize opportunities for
working in conjunction with businesses to tackle the
health challenges facing developing countries.
As Sir George Alleyne, director emeritus of the Pan
American Health Organization, has put it: ‘Few if any
major health programmes with lasting impact globally
have been successful without the involvement and active
participation of the major social partners - the public
sector, the private sector and civil society. Cooperation
among them represents our best chance of surviving
this tsunami of NCDs.’
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